ORCHESTRA BIOMED HOLDINGS IN (OBIO) Fundamental Analysis & Valuation

NASDAQ:OBIO • US68572M1062

Current stock price

4.26 USD
-0.23 (-5.12%)
Last:

This OBIO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. OBIO Profitability Analysis

1.1 Basic Checks

  • In the past year OBIO has reported negative net income.
  • In the past year OBIO has reported a negative cash flow from operations.
  • OBIO had negative earnings in each of the past 5 years.
  • OBIO had a negative operating cash flow in each of the past 5 years.
OBIO Yearly Net Income VS EBIT VS OCF VS FCFOBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 -20M -40M -60M

1.2 Ratios

  • With a Return On Assets value of -46.11%, OBIO is not doing good in the industry: 65.08% of the companies in the same industry are doing better.
  • The Return On Equity of OBIO (-83.55%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -46.11%
ROE -83.55%
ROIC N/A
ROA(3y)-59.27%
ROA(5y)-77.03%
ROE(3y)-113.63%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OBIO Yearly ROA, ROE, ROICOBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 0 -500 -1K

1.3 Margins

  • The Gross Margin of OBIO (99.43%) is better than 99.47% of its industry peers.
  • In the last couple of years the Gross Margin of OBIO has remained more or less at the same level.
  • The Profit Margin and Operating Margin are not available for OBIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 99.43%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.87%
GM growth 5Y0.38%
OBIO Yearly Profit, Operating, Gross MarginsOBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025 0 1K -1K 2K -2K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. OBIO Health Analysis

2.1 Basic Checks

  • OBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for OBIO has been increased compared to 1 year ago.
  • The number of shares outstanding for OBIO has been increased compared to 5 years ago.
  • OBIO has a better debt/assets ratio than last year.
OBIO Yearly Shares OutstandingOBIO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
OBIO Yearly Total Debt VS Total AssetsOBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • OBIO has an Altman-Z score of -1.76. This is a bad value and indicates that OBIO is not financially healthy and even has some risk of bankruptcy.
  • OBIO has a worse Altman-Z score (-1.76) than 61.38% of its industry peers.
  • A Debt/Equity ratio of 0.23 indicates that OBIO is not too dependend on debt financing.
  • OBIO's Debt to Equity ratio of 0.23 is in line compared to the rest of the industry. OBIO outperforms 56.08% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Altman-Z -1.76
ROIC/WACCN/A
WACC10.6%
OBIO Yearly LT Debt VS Equity VS FCFOBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 20M -20M 40M -40M 60M

2.3 Liquidity

  • A Current Ratio of 6.45 indicates that OBIO has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 6.45, OBIO belongs to the top of the industry, outperforming 82.01% of the companies in the same industry.
  • OBIO has a Quick Ratio of 6.43. This indicates that OBIO is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 6.43, OBIO belongs to the best of the industry, outperforming 85.71% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.45
Quick Ratio 6.43
OBIO Yearly Current Assets VS Current LiabilitesOBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. OBIO Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 8.43% over the past year.
  • Looking at the last year, OBIO shows a very strong growth in Revenue. The Revenue has grown by 1169.22%.
  • The Revenue has been growing by 42.49% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)8.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.05%
Revenue 1Y (TTM)1169.22%
Revenue growth 3Y111.68%
Revenue growth 5Y42.49%
Sales Q2Q%12120.16%

3.2 Future

  • OBIO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.85% yearly.
  • The Revenue is expected to grow by 99.36% on average over the next years. This is a very strong growth
EPS Next Y-7.11%
EPS Next 2Y7.13%
EPS Next 3Y16.16%
EPS Next 5Y17.85%
Revenue Next Year-11.98%
Revenue Next 2Y-3.77%
Revenue Next 3Y65.94%
Revenue Next 5Y99.36%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
OBIO Yearly Revenue VS EstimatesOBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 50M 100M 150M 200M 250M
OBIO Yearly EPS VS EstimatesOBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -2 -4 -6 -8

More info and screens

Find the best growth stocksShow best growing peers

0

4. OBIO Valuation Analysis

4.1 Price/Earnings Ratio

  • OBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OBIO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OBIO Price Earnings VS Forward Price EarningsOBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OBIO Per share dataOBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 -1.5

4.3 Compensation for Growth

  • OBIO's earnings are expected to grow with 16.16% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.13%
EPS Next 3Y16.16%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. OBIO Dividend Analysis

5.1 Amount

  • No dividends for OBIO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

OBIO Fundamentals: All Metrics, Ratios and Statistics

ORCHESTRA BIOMED HOLDINGS IN

NASDAQ:OBIO (3/27/2026, 8:00:01 PM)

4.26

-0.23 (-5.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-12
Earnings (Next)05-04
Inst Owners29.89%
Inst Owner Change-4.66%
Ins Owners4.85%
Ins Owner Change16.52%
Market Cap249.30M
Revenue(TTM)33.48M
Net Income(TTM)-52.95M
Analysts81.43
Price Target12.82 (200.94%)
Short Float %2.28%
Short Ratio3.79
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)38.08%
Min EPS beat(2)9.82%
Max EPS beat(2)66.33%
EPS beat(4)4
Avg EPS beat(4)19.74%
Min EPS beat(4)0.13%
Max EPS beat(4)66.33%
EPS beat(8)7
Avg EPS beat(8)10.39%
EPS beat(12)10
Avg EPS beat(12)5.91%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)1594.64%
Min Revenue beat(2)11.42%
Max Revenue beat(2)3177.87%
Revenue beat(4)4
Avg Revenue beat(4)817.19%
Min Revenue beat(4)11.42%
Max Revenue beat(4)3177.87%
Revenue beat(8)5
Avg Revenue beat(8)398.56%
Revenue beat(12)7
Avg Revenue beat(12)262.93%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.38%
PT rev (3m)-7.37%
EPS NQ rev (1m)-4.53%
EPS NQ rev (3m)-4.53%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.04%
Revenue NQ rev (1m)-37.86%
Revenue NQ rev (3m)-37.86%
Revenue NY rev (1m)-13.96%
Revenue NY rev (3m)-14.03%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.45
P/FCF N/A
P/OCF N/A
P/B 3.93
P/tB 3.93
EV/EBITDA N/A
EPS(TTM)-1.52
EYN/A
EPS(NY)-1.63
Fwd EYN/A
FCF(TTM)-0.85
FCFYN/A
OCF(TTM)-0.84
OCFYN/A
SpS0.57
BVpS1.08
TBVpS1.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -46.11%
ROE -83.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 99.43%
FCFM N/A
ROA(3y)-59.27%
ROA(5y)-77.03%
ROE(3y)-113.63%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.87%
GM growth 5Y0.38%
F-Score6
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 149.54%
Cap/Sales 1.46%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.45
Quick Ratio 6.43
Altman-Z -1.76
F-Score6
WACC10.6%
ROIC/WACCN/A
Cap/Depr(3y)155.34%
Cap/Depr(5y)176.84%
Cap/Sales(3y)12.69%
Cap/Sales(5y)17.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.05%
EPS Next Y-7.11%
EPS Next 2Y7.13%
EPS Next 3Y16.16%
EPS Next 5Y17.85%
Revenue 1Y (TTM)1169.22%
Revenue growth 3Y111.68%
Revenue growth 5Y42.49%
Sales Q2Q%12120.16%
Revenue Next Year-11.98%
Revenue Next 2Y-3.77%
Revenue Next 3Y65.94%
Revenue Next 5Y99.36%
EBIT growth 1Y19.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-0.18%
EBIT Next 3Y0.61%
EBIT Next 5Y15.15%
FCF growth 1Y3.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y3.15%
OCF growth 3YN/A
OCF growth 5YN/A

ORCHESTRA BIOMED HOLDINGS IN / OBIO Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ORCHESTRA BIOMED HOLDINGS IN?

ChartMill assigns a fundamental rating of 3 / 10 to OBIO.


Can you provide the valuation status for ORCHESTRA BIOMED HOLDINGS IN?

ChartMill assigns a valuation rating of 0 / 10 to ORCHESTRA BIOMED HOLDINGS IN (OBIO). This can be considered as Overvalued.


Can you provide the profitability details for ORCHESTRA BIOMED HOLDINGS IN?

ORCHESTRA BIOMED HOLDINGS IN (OBIO) has a profitability rating of 1 / 10.


Can you provide the financial health for OBIO stock?

The financial health rating of ORCHESTRA BIOMED HOLDINGS IN (OBIO) is 4 / 10.